The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) ≤ 10µg/m3. Rise in demand is driven by expansion of oncology sector.
BOSTON, MASSACHUSETTS, U.S., November 7, 2017 /EINPresswire.com/ — The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) ≤ 10µg/m3. These high potent intermediates are highly selective in nature and works effectively even with small doses. So they are being increasingly used in many therapeutic applications such as Cancer, CNS (Central Nervous System) disorders, Hormonal disorders, Glaucoma, Cardiovascular and metabolic disorders. The HPAPI global market is growing in terms of revenue and there has been a rise in demand for outsourcing these intermediates manufacturing is driven by expansion of oncology sector, which is the fastest among overall pharmaceutical sector, increase in number of ADCs, growing number of CMOs for manufacturing.
As estimated by IQ4I Research and Consultancy, the HPAPI global market was estimated to reach $27,293.4 million by 2023 growth at high single digit CAGR. HPAPI market is mainly classified by customer base, business type, molecule type and Applications. The global HPAPI market is broadly classified as Innovative HPAPI and Generic HPAPI based on customer base. Innovative HPAPI holds the maximum share, However, Generic HPAPI are expected to grow at a strong CAGR because of increase in number of generic HPAPI manufacturers, increase in government initiatives to use of generic HPAPI drugs, nearing patent expires (Patent Cliffs) of drugs. Based on business type, the market is classified into Captive HPAPI & Merchant HPAPI. Captive HPAPI holds the maximum share and Merchant HPAPI is expected to grow at a strong CAGR. HPAPI market is segmented on the basis of molecule type as Synthetic HPAPI and Biotech HPAPI. Synthetic HPAPI holds the maximum share. However, the Biotech HPAPI is expected to grow at a strong CAGR as there is an increasing focus on research & development of use of these for many therapies. HPAPI market application segment is classified into Oncology, Cardiovascular, Central Nervous system, Hormonal, Glaucoma, Infectious, metabolic, Inflammation and other therapeutic applications. Oncology holds the maximum share among applications and estimated to grow at a strong CAGR.
The HPAPI market is highly fragmented and the major seven players in the market are Merck KGaA (Germany), Alkermes (Ireland), Lonza Group (Switzerland), Pfizer (U.S.), Dishman Group (India), Cambrex Corporation (U.S.) and Teva Pharmaceutical Industries (Israel). Through acquisitions, few larger pharmaceutical companies are trying to enter the market. For instance, Merck KGaA (Germany) acquired sigma Aldrich in 2015 and thus entered the HPAPI market and now is the global leader in the market.
Geographically, North America commanded the largest share in the HPAPI global market and is expected to grow with double digit rate from 2016-2023. The Asia-Pacific region with emerging countries represents huge growth opportunities for the HPAPI market to flourish.
Major players in HPAPI market include Alkermes plc (Ireland), Cambrex Corporation (U.S.), Dishman Group (India), Dr. Reddy’s Laboratories (India), Lonza Group (Switzerland), Novasep (U.S.), Patheon N.V.(Netherland),(Acquired by ThermoFisher Scientific), Pfizer (U.S.), Merck KGaA (Germany), Teva Pharmaceutical Industries (Israel).
Other key players in the HPAPI market include Evonik Industries (Germany), Fermion (Finland), Johnson Matthey (U.K.), Piramal Pharma Solution (India), Stason Pharmaceuticals (U.S.), Wuxi PharmaTec (China), Catalent Pharma Solutions Inc. (U.S.)
Mr. Satish Biruddukota
IQ4I Research & Consultancy Pvt Ltd.,
email us here
Source: EIN Presswire